Company
Headquarters: Velizy-Villacoublay, France
Employees: 139
CEO: Mr. Stephane Piat
€45.9 Million
EUR as of Jan. 1, 2025
US$47.8 Million
| Company | Market Cap (USD) |
|---|---|
| Abbott | $213.72 B |
| Stryker | $150.01 B |
| Boston Scientific Corporation | $149.80 B |
| Medtronic | $114.44 B |
| Shenzhen Mindray Bio-Medical Electronics Co. Ltd | $47.37 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It also develops orthotopic, bioprosthetic, self-regulating, pulsatile, and implantable systems, as well as power supply systems. The company was founded in 2008 and is based in Vélizy-Villacoublay, France.
Carmat SA has the following listings and related stock indices.
Stock: Euronext: ALCAR wb_incandescent
Stock: FSX: CXT wb_incandescent